ABSI AbSci Corporation

Absci Corporation (Nasdaq: ABSI), a data-first generative AI drug creation company, today announced the company will be participating in the following upcoming investor conferences.

• Morgan Stanley 22nd Annual Global Healthcare ConferenceFireside chat on Thursday, September 5th at 5:35 p.m. Eastern Time

• Citi 2024 Global TMT Conference Fireside chat on Friday, September 6th at 8:20 a.m. Eastern Time

• H.C. Wainwright 26th Annual Global Investment ConferenceFireside chat on Tuesday, September 10th at 12:00 p.m. Eastern Time

Interested parties may access live and archived webcasts of these events on the company’s investor relations website at: investors.absci.com.

About Absci

Absci is a data-first generative AI drug creation company that combines AI with scalable wet lab technologies to create better biologics for patients, faster. Our Integrated Drug Creation™ platform unlocks the potential to accelerate time to clinic and increase the probability of success by simultaneously optimizing multiple drug characteristics important to both development and therapeutic benefit. With the data to train, the AI to create, and the wet lab to validate, we can screen billions of cells per week, allowing us to go from AI-designed candidates to wet lab-validated candidates in as little as six weeks. Absci’s headquarters is in Vancouver, WA, with our AI Research Lab in New York City and an Innovation Center in Zug, Switzerland. Visit www.absci.com and follow us on LinkedIn (@absci), X (Twitter) (@Abscibio), and YouTube.

Investor ContactAlex KhanVP, Finance & Investor Relationsinvestors@absci.com

Media Contactpress@absci.com